Company intelligence / Profile preview
Amyndas Pharmaceuticals
Jackson, Wyoming, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Amyndas has initiated a Phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis as of August 2019[9]
- Therapeutic areas
- Infectious DiseasesOphthalmologyHematologyNephrologyImmunologyCardiovascular
- Modalities
- Complement inhibitorspeptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Participation in EU funded FP7 project DIREKT with 12 European partners, headed by the University of Uppsala[5]
Beyond the preview
Go deeper on Amyndas Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amyndas Pharmaceuticals.